When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.
Achieving diversity and inclusion in medical research is essential for advancing healthcare, discovering novel drug therapies, and achieving overall health equity.
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed.
The global demand for state-of-the-art research facilities is limited by the current supply, leaving many regions unable to support innovation outside of established hubs like Boston, San D